Drug discovery paradigms: Past, present, future - A centennial symposium of the American Society for Pharmacology and Experimental Therapeutics 6 April 2008, San Diego, USA

Expert Opinion on Drug Discovery

Volumn 3, Issue 9, 2008, Pages 1145-1154

  Cavero, Icilio ^a   Kaplan, Harvey R ^a,b  

^a Department of Pharmacology ^*  (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

ASPET; Biomarkers; CNS drugs; Drug discovery; GPCR; Mouse genetics; Receptors; Translational medicine

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; CENTRAL NERVOUS SYSTEM AGENTS; G PROTEIN COUPLED RECEPTOR; GENE PRODUCT; PROTEIN LG293; UNCLASSIFIED DRUG;

BIOTECHNOLOGY; CONFERENCE PAPER; DRUG DESIGN; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RESEARCH; DRUG TARGETING; EXPERIMENTAL ANIMAL; GENETIC MANIPULATION; HISTORY OF MEDICINE; HOMOLOGOUS RECOMBINATION; INBRED STRAIN; MEDICAL SOCIETY; NONHUMAN; PHARMACOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR INTRINSIC ACTIVITY; SYMPOSIUM; TRANSGENIC ANIMAL;

EID: 52649165274     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.9.1145     Document Type: Conference Paper

References (39)

1. Parascandola J. A brief history of ASPET on its centennial anniversary. Mol Interv 2007;7:288-302
2. Rubin RP. A brief history of great discoveries in pharmacology: in celebration of the centennial anniversary of the founding of the American Society of Pharmacology and Experimental Therapeutics. Pharmacol Rev 2007;59:289-359
3. The American Society for Pharmacology and Experimental Therapeutics 1908-2008. ASPET Centennial Compendium. Published by American Society for Pharmacology and Experimental Therapeutics, Inc., Bethesda, Maryland, USA; 2008
4. Chen KK. The First Sixty Years (1908-1969): The American Society for Pharmacology and Experimental Therapeutics Inc., Judd & Dirtweiler Inc., Washington, DC, USA; 1969
5. Clark AJ. The reaction between acetyl choline and muscle cells. J Physiol 1926;61:530-46
6. Clark AJ. The antagonism of acetyl choline by atropine. J Physiol 1926;61:547-56
7. Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol 1948;153:586-600
8. Paton WD, Zaimis EJ. The pharmacological actions of polymethylene bistrimethyl-ammonium salts. Br J Pharmacol Chemother 1949;4:381-400
9. Black JW, Duncan WA, Durant CJ, et al. Definition and antagonism of histamine H2-receptors. Nature 1972;236:385-90
10. North RA, Williams JT, Surprenant A, Christie MJ. Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. Proc Natl Acad Sci USA 1987;84:5487-91
11. Seeman P, Lee T, Chau-Wong M, et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717-9
12. Hammer R, Berrie CP, Birdsall NJ, et al. Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 1980;283:90-2
13. Cherezov V, Rosenbaum DM, Hanson, et al. High-resolution crystal structure of an engineered human beta2-adrenergic G-protein-coupled receptor. Science 2007;318:1258-65
14. Rasmussen SG, Choi HJ, Rosenbaum DM, et al. Crystal structure of the human beta2-adrenergic G-protein-coupled receptor. Nature 2007;450:383-7
15. Sneader W. Drug discovery. A history. John Wiley & Sons: Mondon; 2005
16. Gilchrist A. A perspective on more effective GPCR-targeted drug discovery efforts. Exp Opin Drug Discov 2008;3:375-89
17. Gupta A, Rozenfeld R, Gomes I, et al. Post-activation-mediated changes in opioid receptors detected by N-terminal antibodies. J Biol Chem 2008;283:10735-44
18. Lane JR, Henderson D, Powney B, et al. Antibodies that identify only the active conformation of Gi family G protein α-subunits. FASEB J 2008;22:1924-32
19. Milligan G. Constitutive activity and inverse agonists of g protein coupled receptors: a current perspective. Mol Pharmacol 2003;264:1271-6
20. Pantel J, Legendre M, Cabrol S, et al. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J Clin Invest 2006;116:760-8
21. Gurevich VV, Gurevich EV. How and why do GPCRs dimerize? Trend Pharmacol Sci 2008;29:234-40
22. Xu H, Staszewski L, Tang H, et al. Different functional roles of T1R subunits in the heteromeric taste receptors. Proc Natl Acad Sci USA 2004;101:14258-63
23. Milligan G, Smith. Allosteric modulation of heterodimeric G-protein-coupled receptors. Trend Pharmacol Sci 2007;28:615-20
24. Palmiter RD, Brinster RL, Hammer RE, et al. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature 1982;300:611-5
25. Maniatis T, Fritsch EF, Sambrook J. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory: New York; 1982
26. Houdebine L-A. Transgenic animal models in biomedical research. Methods Mol Biol 2007;360:163-202
27. Abuin A, Holt KH, Platt KA, et al. Full-speed mammalian genetics: in vivo target validation in the drug discovery process. Trends Biotechnol 2002;20:36-42
28. Auwerx J, Avner P, Baldock R, et al. The European dimension for the mouse genome mutagenesis program. Nat Genet 2004;36:925-7
29. Understanding Human Disease Through Mouse Genetics. Available from: http://www.eumorphia.org/
30. Mouse Genome Informatics. Available from: http://www.informatics.jax.org/
31. Zambrowicz BP, Turner CA, Sands AT. Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr Opin Pharmacol 2003;3:563-70
32. Zambrowicz BP, Sands AT. Knockouts model the 100 best-selling drugs - will they model the next 100? Nat Rev Drug Discov 2003;2:38-51
33. Hopkins AL, Witty MJ, Nwaka S. Mission possible. Nature 2007;449:166-9
34. Stagnation and innovation: challenge and opportunity on the critical path to new medical product. 2004. Available from: http://www.fda.gov/oc/ initiatives/criticalpath/whitepaper.pdf
35. Cuatrecasas R Drug discovery in jeopardy. J Clin Invest 2006;116:2837-42
36. French ED. Academic pharmacologists: confronting new challenges in educational programs of graduate and health care programs. J Pharmacol Exp Ther 2004;309:441-3
37. Chin-Dusting J, Mizrahi J, Jenings G, et al. Outlook: finding improved medicines: the role of academic-industrial Nat Rev Drug Discov collaborations. 2005;4:891-7
38. Neilson GL, Martin KL, Powers E. The secrets to successful strategy execution. Harv Bus Rev 2008;86:61-70
39. Cavero I. Safety Pharmacology Society: 7th Annual Meeting 20-21 September 2007; Edinburgh, UK. Expert Opin Drug Saf 2008;7:91-100